Remote smartwatch monitoring of walking and daily function in bone cancer
Musculoskeletal Cancers Remote Monitoring and Care
NA · Case Comprehensive Cancer Center · NCT07129226
This study tests whether a smartwatch can track walking stability and daily activities to spot changes during treatment for people with osteosarcoma or metastatic bone disease.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Case Comprehensive Cancer Center (other) |
| Locations | 1 site (Cleveland, Ohio) |
| Trial ID | NCT07129226 on ClinicalTrials.gov |
What this trial studies
Participants with primary osteosarcoma or metastatic bone disease of the lower limbs or pelvis will wear a consumer smartwatch and use a mobile app while completing weekly electronic questionnaires. The device will collect raw sensor data (accelerometer, gyroscope, photoplethysmography) to derive gait, activity, and physiologic metrics alongside patient-reported outcomes. Investigators will analyze how these measures change during non-surgical and surgical treatment and whether the watch signals can predict mobility decline or complications. The protocol also measures feasibility by tracking adherence to wearing the watch for at least 12 hours per day and completion rates for app-based questionnaires.
Who should consider this trial
Good fit: Ideal candidates are ambulatory adults with primary osteosarcoma or metastatic bone disease of the lower extremities or pelvis who are undergoing evaluation or treatment, have recent home ambulation, and own or can use an iOS/Android smartphone to run the study app.
Not a fit: Patients who cannot wear a watch on the wrist (due to amputation, wrist tattoos, skin conditions), cannot tolerate 12 hours/day wear, lack a compatible smartphone, or are non-ambulatory are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, this approach could give earlier warning of mobility decline and enable personalized, proactive interventions to prevent complications.
How similar studies have performed: Prior work with consumer wearables has shown feasibility for collecting gait and physiologic signals and the investigators have used a similar platform in neuro-oncology, but using smartwatches specifically to predict complications in musculoskeletal cancer care remains relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * primary sarcoma or metastatic bone disease of the lower extremities or pelvis. * undergoing evaluation for (or have recently undergone) non-surgical or surgical intervention. * recent history of home ambulation. Exclusion Criteria: * under 18 years of age at the time of study enrolment * inability to comprehend consent form and give informed consent * no access to a smartphone (iOS or Android) to interface with watch application * tattoos located on the skin of the wrist or forearm where the watch will be placed or other skin conditions preventing adequate sensor function * amputation or other disease of the arm or skin that prevents wear of a smart-watch device * inability to tolerate watch for at least 12 hours per day on at least 80% of days in a four-week period
Where this trial is running
Cleveland, Ohio
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation — Cleveland, Ohio, United States (RECRUITING)
Study contacts
- Study coordinator: Zachary Burke, MD
- Email: burkez@ccf.org
- Phone: 216-445-9174
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Osteosarcoma, Metastatic Bone Disease, prophylactic surgery